Insider Selling: Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells 22,355 Shares of Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) General Counsel David Aaron Lehman sold 22,355 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.65, for a total transaction of $171,015.75. Following the transaction, the general counsel now owns 175,496 shares of the company's stock, valued at approximately $1,342,544.40. This represents a 11.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Pulmonx Trading Up 0.5 %

LUNG traded up $0.04 during trading on Friday, reaching $7.48. 245,140 shares of the company's stock were exchanged, compared to its average volume of 335,956. Pulmonx Co. has a one year low of $5.46 and a one year high of $10.01. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $297.67 million, a PE ratio of -5.19 and a beta of 0.50. The firm has a fifty day moving average price of $6.96 and a two-hundred day moving average price of $6.94.

Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The firm had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. As a group, equities research analysts forecast that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Pulmonx

Institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its stake in shares of Pulmonx by 2.6% in the 3rd quarter. State Street Corp now owns 747,028 shares of the company's stock valued at $6,193,000 after purchasing an additional 18,592 shares during the last quarter. Parkman Healthcare Partners LLC bought a new stake in shares of Pulmonx in the 3rd quarter valued at $1,711,000. Geode Capital Management LLC boosted its stake in shares of Pulmonx by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 892,786 shares of the company's stock valued at $7,403,000 after purchasing an additional 11,151 shares during the last quarter. Polar Asset Management Partners Inc. bought a new stake in shares of Pulmonx in the 3rd quarter valued at $893,000. Finally, Millrace Asset Group Inc. bought a new stake in shares of Pulmonx in the 3rd quarter valued at $1,390,000. 91.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company lowered their price objective on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Wednesday, December 11th. Citigroup reiterated a "neutral" rating and set a $7.50 price objective (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.